Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Catheter Precision (VTAK) Shares Outstanding (2017 - 2025)

Catheter Precision has reported Shares Outstanding over the past 9 years, most recently at $1.7 million for Q4 2025.

  • Quarterly Shares Outstanding rose 13640.16% to $1.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.7 million through Dec 2025, up 13640.16% year-over-year, with the annual reading at $1.7 million for FY2025, 13640.16% up from the prior year.
  • Shares Outstanding was $1.7 million for Q4 2025 at Catheter Precision, up from $12656.0 in the prior quarter.
  • Over five years, Shares Outstanding peaked at $1.4 billion in Q3 2022 and troughed at $3703.0 in Q1 2024.
  • The 5-year median for Shares Outstanding is $181723.0 (2024), against an average of $84.1 million.
  • Year-over-year, Shares Outstanding crashed 99.68% in 2023 and then skyrocketed 13640.16% in 2025.
  • A 5-year view of Shares Outstanding shows it stood at $140190.0 in 2021, then soared by 915.05% to $1.4 million in 2022, then crashed by 97.4% to $36993.0 in 2023, then crashed by 65.79% to $12656.0 in 2024, then skyrocketed by 13640.16% to $1.7 million in 2025.
  • Per Business Quant, the three most recent readings for VTAK's Shares Outstanding are $1.7 million (Q4 2025), $1.6 million (Q3 2025), and $12656.0 (Q2 2025).